• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Announces Appointment of Three New Members to the Company's Executive Management Committee

    4/10/24 4:05:00 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email

    Joining Henry Schein's EMC are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced that it has appointed three new members to the Company's Executive Management Committee (EMC) – Steve Boggan and Bianka Wilson, who were recently named Co-CEOs of the Company's Global Oral Reconstruction Group (GORG), and Tom Popeck, CEO of the Company's Healthcare Specialties Group (HSG).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410230713/en/

    Bianka Wilson, Co-Chief Executive Officer, Global Oral Reconstruction Group, Henry Schein, Inc. (Photo: Business Wire)

    Bianka Wilson, Co-Chief Executive Officer, Global Oral Reconstruction Group, Henry Schein, Inc. (Photo: Business Wire)

    GORG includes the Company's comprehensive portfolio of premium value and value implant lines and a full range of biomaterial products. HSG includes a range of company-owned manufacturing brands in the high-growth endodontic, orthodontic, and orthopedic markets.

    "We are delighted to welcome three strong and proven leaders to the Henry Schein Executive Management Committee," said Stanley Bergman, Chairman and Chief Executive Officer of Henry Schein, Inc. "Steve, Bianka, and Tom have each demonstrated vision and commitment in inspiring and leading our teams to excellence in a quickly changing global healthcare marketplace. Our senior leadership team will benefit greatly from the added perspectives of these seasoned professionals."

    The GORG and HSG businesses are central to advancing the Company's BOLD+1 strategic plan, in particular the building of higher-growth and higher-margin specialty products and services offerings that complement our distribution, software, and value-added businesses. Together, the Company is leveraging these businesses to broaden and deepen relationships with customers.

    Mr. Boggan joined Henry Schein in 2013 with the Company's acquisition of BioHorizons, which he joined as a start-up in 1995 and has led as President and CEO since 1999. As Co-CEO of GORG, Mr. Boggan will lead commercial operations in North and South America and the Middle East as well as global marketing.

    Ms. Wilson joined Henry Schein in 2018 after a successful 25-year career in finance and consulting. Prior to Henry Schein, she served as Group CFO of Ascom Holding AG, a Swiss public company in the medical communication technology sector and, prior to that, as Advisory and Global Account Lead Partner at KPMG. Ms. Wilson had been serving as Chief Financial Officer of GORG and, as Co-CEO, she will lead strategy, finance, and human resources as well as the group's business in Europe and APAC.

    Mr. Popeck joined Henry Schein in 2019 with more than 20 years of sales leadership and general management experience, including extensive experience in the medical device sector. Prior to joining Henry Schein, he spent over two decades leading businesses in orthopedics and industrial manufacturing, including spending 11 years at Stryker, where he held various leadership roles, including leading Stryker's Foot & Ankle business unit as Vice President and General Manager. In 2023, he was promoted to President of Henry Schein's Healthcare Specialties Group.

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240410230713/en/

    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein's 28th Annual 'Back to School' Program Supports Students Worldwide

    With Backpacks Full of Supplies, Team Schein Helps Equip Children to Thrive in the Classroom For the 28th consecutive year, Henry Schein, Inc. (NASDAQ:HSIC) is helping students worldwide start the academic year off right through its "Back to School" program, a flagship initiative of Henry Schein Cares, the Company's global corporate citizenship program. Team Schein Members (TSMs) at 45 locations in the U.S., Canada, Italy, Spain, the U.K., and Ireland are helping more than 5,200 students gain confidence and excitement for the school year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818808698/en/On August 14, Henry Schein

    8/19/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Launches Forms to Make Patient Check-In Easier and Faster

    With a native end-to-end workflow in Dentrix and Dentrix Ascend, the new Forms cuts manual work and extra logins for a smoother start to every visit Henry Schein One, the most connected solution in dental technology, today launched Forms for Dentrix and Dentrix Ascend (Ascend). With more than 1,000 dental practices adopting Forms just this month, this fully integrated digital intake solution is already simplifying the pre-appointment process for both patients and dental teams. With mobile-friendly and customizable forms, ID and insurance card scanning, and secure two-factor authentication, Forms makes patient check-in virtually touchless. And early results show that 90% of patients comple

    7/30/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

    7/14/25 8:40:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on Henry Schein with a new price target

    Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

    2/14/25 7:05:26 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 10-Q filed by Henry Schein Inc.

    10-Q - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 3:03:18 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 6:15:01 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    7/15/25 7:10:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Kkr Hawaii Holdings L.P. claimed ownership of 15,263,662 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/15/25 9:30:38 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 7:00:45 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 1,650 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.51% to 322,097 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 4:50:03 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

    7/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2025 Financial Results

    First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

    5/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care